CN107502592A - A kind of immunocyte serum free medium and preparation method thereof - Google Patents

A kind of immunocyte serum free medium and preparation method thereof Download PDF

Info

Publication number
CN107502592A
CN107502592A CN201710953958.6A CN201710953958A CN107502592A CN 107502592 A CN107502592 A CN 107502592A CN 201710953958 A CN201710953958 A CN 201710953958A CN 107502592 A CN107502592 A CN 107502592A
Authority
CN
China
Prior art keywords
vitamin
medium
serum free
free medium
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710953958.6A
Other languages
Chinese (zh)
Inventor
冯继锋
陈丹
吴建中
马蓉
张君莹
刘思文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST OF ONCOLMA PREVENTION AND CURE JIANGSU PROV
Jiangsu Cancer Hospital
Original Assignee
INST OF ONCOLMA PREVENTION AND CURE JIANGSU PROV
Jiangsu Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST OF ONCOLMA PREVENTION AND CURE JIANGSU PROV, Jiangsu Cancer Hospital filed Critical INST OF ONCOLMA PREVENTION AND CURE JIANGSU PROV
Priority to CN201710953958.6A priority Critical patent/CN107502592A/en
Publication of CN107502592A publication Critical patent/CN107502592A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/35Polyols, e.g. glycerin, inositol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/36Lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/44Thiols, e.g. mercaptoethanol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/46Amines, e.g. putrescine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/33Insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种免疫细胞无血清培养基及其制备方法。本发明的无血清培养基的主要成分为:聚胺、胰岛素、胆固醇、枸橼酸铁、肌醇和抗氧化剂和白细胞介素15。本发明的无血清培养基对人体安全,能提高CIK细胞增殖速度和活化率。并且有成分简单、性状稳定、批间差异小、便于质控、诱导CIK增殖效率高、CD3+CD56+的阳性比例高,培养获得的CIK细胞质量稳定的优点,对于免疫治疗的推广应用具有重要意义。The invention discloses an immune cell serum-free culture medium and a preparation method thereof. The main components of the serum-free medium of the present invention are: polyamine, insulin, cholesterol, ferric citrate, inositol, antioxidant and interleukin-15. The serum-free culture medium of the invention is safe for human body and can increase the proliferation speed and activation rate of CIK cells. And it has the advantages of simple ingredients, stable properties, small batch-to-batch difference, convenient quality control, high efficiency of inducing CIK proliferation, high positive ratio of CD3 + CD56 + , and stable quality of CIK cells obtained by culture, which is of great importance for the promotion and application of immunotherapy significance.

Description

一种免疫细胞无血清培养基及其制备方法A kind of immune cell serum-free culture medium and preparation method thereof

技术领域technical field

本发明属于生物医学技术领域,具体涉及一种免疫细胞无血清培养基及其制备方法和用途。The invention belongs to the technical field of biomedicine, and in particular relates to a serum-free culture medium for immune cells and its preparation method and application.

背景技术Background technique

细胞因子诱导的肿瘤杀伤细胞(CIKs)是将人外周血单个核细胞在体外用多种细胞因子共同培养而获得的一群异质细胞群,因其兼具有T淋巴细胞强大的抗瘤活性和NK细胞的非主要组织相容抗原(MHC)限制性杀瘤特点,从而成为肿瘤过继免疫治疗的重要手段之一。CIK细胞由于具有较强的增生能力和细胞毒性且杀瘤谱广而受到广泛的重视,在一些实体瘤、血液肿瘤及血液病骨髓移植后的免疫治疗中已显示出良好的应用前景。能否获得足够数量的效应细胞及效应细胞的杀伤活性与CIK细胞治疗的临床疗效有着密切的关系。研究已表明,CIK的主要效应细胞为CD3+/CD56+双阳性细胞。CIK细胞培养后CD3+/CD56+细胞所占细胞总数的比例是重要观察指标。Cytokine-induced tumor killer cells (CIKs) are a group of heterogeneous cell populations obtained by co-culturing human peripheral blood mononuclear cells with various cytokines in vitro, because they have both strong anti-tumor activity of T lymphocytes and The non-major histocompatibility antigen (MHC)-restricted tumor killing characteristics of NK cells have become one of the important means of tumor adoptive immunotherapy. CIK cells have received extensive attention due to their strong proliferative ability, cytotoxicity and broad tumor killing spectrum. They have shown good application prospects in the immunotherapy of some solid tumors, hematological tumors and hematological diseases after bone marrow transplantation. Whether a sufficient number of effector cells can be obtained and the killing activity of effector cells are closely related to the clinical efficacy of CIK cell therapy. Studies have shown that the main effector cells of CIK are CD3+/CD56+ double positive cells. The ratio of CD3+/CD56+ cells to the total number of cells after CIK cell culture is an important observation index.

传统对CIK细胞治疗的通用流程是将患者外周血中采集的单个核细胞在体外经IFN-γ、CD3单抗、IL-1α以及IL-2修饰、刺激、培养、增殖后回输到患者体内,从而杀伤肿瘤。目前培养方法细胞增殖慢、倍增时间长、CD3+/CD56+双阳性细胞比率不稳定。大部分实验室体外培养人免疫细胞主要以添加人AB血清或FBS来维持免疫细胞生长。但动物或人血清中含有病原体或不确定物质,再加上人AB血清来源困难,会对培养细胞带来危险或不确定的危害。并且传统培养基成分不稳定无法进行后期质量控制,无法在工业上大规模生产。因此亟需开发能克服上述缺陷的无血清培养基。The general process of traditional CIK cell therapy is to infuse the mononuclear cells collected from the patient's peripheral blood into the patient after being modified, stimulated, cultured and proliferated by IFN-γ, CD3 monoclonal antibody, IL-1α and IL-2 in vitro , thereby killing the tumor. The current culture method has slow cell proliferation, long doubling time, and unstable ratio of CD3+/CD56+ double positive cells. Most laboratories culture human immune cells in vitro mainly by adding human AB serum or FBS to maintain the growth of immune cells. However, animal or human serum contains pathogens or uncertain substances, and the source of human AB serum is difficult, which will bring dangerous or uncertain hazards to cultured cells. Moreover, the components of the traditional culture medium are unstable and cannot be used for quality control in the later stage, and cannot be mass-produced in industry. Therefore, there is an urgent need to develop a serum-free medium that can overcome the above-mentioned defects.

发明内容Contents of the invention

本发明的目的在于提供一种免疫细胞无血清培养基及其制备方法和用途。该培养基对人体安全,并能提高CIK细胞表型(CD3+CD56+)双阳性率的培养基。The object of the present invention is to provide an immune cell serum-free culture medium and its preparation method and application. The culture medium is safe for human body and can increase the double-positive rate of CIK cell phenotype (CD3+CD56+).

一种免疫细胞无血清培养基,培养基成分包括基础培养基、聚胺、胰岛素、胆固醇、枸橼酸铁、肌醇和抗氧化剂;所述基础培养基是RPMI-1640。An immune cell serum-free medium, the medium components include basal medium, polyamine, insulin, cholesterol, ferric citrate, inositol and antioxidant; the basal medium is RPMI-1640.

每升培养基包括:胆固醇13.2mg/L;胰岛素20mg/L;枸橼酸铁2mg/L;NaHCO3 2g/L;乙醇胺1.22mg/L;亚油酸1mg/L;肌醇19mg/L;左旋谷氨酸584mg/L;丙酮酸钠110mg/L;2巯基乙醇0.78mg/L;1硫代甘油5.41mg/L;非必须氨基酸20ml/L;维生素10ml/L;聚胺添加物3.31mg/L;抗氧化剂0.52mg/L;油酸1mg/L。Each liter of medium includes: cholesterol 13.2mg/L; insulin 20mg/L; iron citrate 2mg/L; NaHCO 3 2g/L; ethanolamine 1.22mg/L; linoleic acid 1mg/L; inositol 19mg/L; L-glutamic acid 584mg/L; sodium pyruvate 110mg/L; 2-mercaptoethanol 0.78mg/L; 1-thioglycerol 5.41mg/L; non-essential amino acid 20ml/L; vitamin 10ml/L; polyamine additive 3.31mg /L; antioxidant 0.52mg/L; oleic acid 1mg/L.

所述非必须氨基酸为甘氨酸、丙氨酸、脯氨酸、酪氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸中的一种或一种以上。The non-essential amino acid is one or one of glycine, alanine, proline, tyrosine, serine, cysteine, asparagine, glutamine, aspartic acid, glutamic acid above.

所述维生素为维生素A,维生素B1,维生素B2,维生素PP,维生素B4,维生素B5,维生素B6,生物素,维生素B9,维生素B12,肌醇,维生素C,维生素D,维生素E,维生素K中的一种或一种以上。The vitamins are vitamin A, vitamin B1, vitamin B2, vitamin PP, vitamin B4, vitamin B5, vitamin B6, biotin, vitamin B9, vitamin B12, inositol, vitamin C, vitamin D, vitamin E, vitamin K One or more than one.

所述培养基成分还包括IL-15(白细胞介素15),IFN-γ,CD3,IL-1α,IL-2因子中的一种或一种以上。The medium components also include one or more of IL-15 (interleukin-15), IFN-γ, CD3, IL-1α, and IL-2 factors.

本发明的有益效果:本发明的无血清培养基对人体安全,能稳定CIK细胞增殖速度和提高细胞CD3+CD56+,并且有成分简单、性状稳定、批间差异小、便于质控、诱导CIK增殖效率高、CD3+CD56+的阳性比例高,培养获得的CIK细胞质量稳定的优点,对于免疫治疗的推广应用具有重要意义。Beneficial effects of the present invention: the serum-free medium of the present invention is safe for human body, can stabilize CIK cell proliferation rate and increase cell CD3 + CD56 + , and has simple ingredients, stable properties, small batch-to-batch difference, convenient quality control, and induction of CIK The advantages of high proliferation efficiency, high CD3 + CD56 + positive ratio, and stable quality of CIK cells obtained from culture are of great significance for the promotion and application of immunotherapy.

附图说明Description of drawings

图1为1-3号培养基与实施例1的无血清培养基培养的CIK细胞表型流式细胞术检测结果对比图;Fig. 1 is the comparative figure of the CIK cell phenotype flow cytometry detection result that culture medium No. 1-3 and the serum-free medium of embodiment 1 cultivate;

图2为实施例1的无血清培养基与Takara公司的H3培养基培养的CIK细胞表型流式细胞术检测结果对比图。Fig. 2 is a comparison chart of flow cytometry detection results of CIK cell phenotypes cultured in the serum-free medium of Example 1 and the H3 medium of Takara Company.

图3为实施例1的无血清培养基在添加IL-15之后,CIK细胞表型流式细胞术检测结果对比图。Fig. 3 is a comparison chart of CIK cell phenotype flow cytometry detection results after IL-15 is added to the serum-free medium in Example 1.

具体实施方式detailed description

下面结合附图和具体实施例对本发明做进一步说明。The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.

实施例1Example 1

将一袋一升装RPMI 1640(Gibco)用超纯水搅拌溶解,依次加入下表所添加物质(表1),最终定容至1L,搅拌溶解,调节PH值至7.0左右,0.22μm滤膜过滤除菌,4℃保存。其中pH值保持在6.8-7.2之间,最佳pH值保持在7.0。Stir and dissolve a bag of 1 liter RPMI 1640 (Gibco) with ultrapure water, add the substances added in the following table (Table 1) in sequence, and finally set the volume to 1L, stir and dissolve, adjust the pH value to about 7.0, and use a 0.22μm filter membrane Sterilize by filtration and store at 4°C. Wherein the pH value is kept between 6.8-7.2, and the optimum pH value is kept at 7.0.

表1.免疫细胞无血清培养基配制表Table 1. Preparation of serum-free medium for immune cells

取患者外周血60ml,转入2支50ml离心管,2200rpm离心10min,吸取上层黄色血浆,转移至新的50ml离心管中,置于56℃灭活25min,4℃冷藏10min,3000rpm,4℃,离心15min,取上清分装后置于4℃保存备用。将下层红细胞缓缓加入已装有淋巴细胞分离液的2支50ml离心管中,400g离心30min。取中间层白色细胞,NaCl清洗2次后,将细胞种于1-4号的培养基中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。Take 60ml of peripheral blood from the patient, transfer it to two 50ml centrifuge tubes, centrifuge at 2200rpm for 10min, absorb the upper yellow plasma, transfer to a new 50ml centrifuge tube, inactivate at 56°C for 25min, refrigerate at 4°C for 10min, 3000rpm, 4°C, After centrifugation for 15 min, the supernatant was collected and stored at 4°C for later use. Slowly add the red blood cells in the lower layer to two 50ml centrifuge tubes filled with lymphocyte separation medium, and centrifuge at 400g for 30min. Take the white cells in the middle layer, wash them twice with NaCl, plant the cells in No. 1-4 medium, add IFN-γ, CD3, IL-1α, and IL-2 factors, and continue to culture for 14 days.

1号培养基:RPMI 1640。Medium No. 1: RPMI 1640.

2号培养基:RPMI 1640+白蛋白。Medium 2: RPMI 1640+albumin.

3号培养基:RPMI 1640+UltraKURE。Medium 3: RPMI 1640+UltraKURE.

4号培养基:RPMI 1640+表一配方(C922)。Medium No. 4: RPMI 1640+Formulation in Table 1 (C922).

实施例2Example 2

前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于H3和培养基中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较Takara商品化的H3培养基与我们本实施例培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were planted in H3 and medium, and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. Compare the effects of Takara's commercialized H3 medium and our medium in this example on cell proliferation rate, survival rate and cell phenotype.

实施例3Example 3

前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于培养基和培养基外加白介素15(0.5ng/mL)中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较IL-15对我们本发明培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were planted in the medium and the medium plus interleukin 15 (0.5ng/mL), and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. Compare the effects of IL-15 on our culture medium of the present invention on cell proliferation rate, survival rate and cell phenotype.

验结果表明,在培养14天后,CD3+CD56+双阳性细胞百分率:1-3号组均小于3%,4号培养基为27.2%(图1)。与商品化的H3对比,与H3组的细胞扩增率差不多,细胞存活率都在98%左右。但在细胞表型方面,H3组CD3+CD56+双阳性细胞百分率为17.3%,而4号培养基为23.7%(图2)。比H3提高了6个百分点。在4号培养基中添加了IL-15(0.5ng/mL)可以有效提高CD3+CD56+双阳性细胞百分率,CIK细胞活化率提高了一倍以上(图3)。The experimental results showed that after 14 days of culture, the percentage of CD3 + CD56 + double-positive cells: groups 1-3 were all less than 3%, and culture medium 4 was 27.2% (Fig. 1). Compared with the commercialized H3, the cell expansion rate of the H3 group is almost the same, and the cell survival rate is about 98%. But in terms of cell phenotype, the percentage of CD3 + CD56 + double-positive cells in H3 group was 17.3%, while that in No. 4 medium was 23.7% (Fig. 2). 6 percentage points higher than H3. Adding IL-15 (0.5ng/mL) to No. 4 medium can effectively increase the percentage of CD3 + CD56 + double-positive cells, and the activation rate of CIK cells has more than doubled (Figure 3).

实施例4Example 4

前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于培养基和培养基外加苞藜提取物(3mg/L)中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较苞藜提取物对我们本发明培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were planted in the medium and the medium plus the extract of Chenopodium quinoa (3mg/L), and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. To compare the effect of the extract of quinoa quinoa on our culture medium of the present invention on cell proliferation rate, survival rate and cell phenotype.

所述苞藜提取物的提取方法如下:将苞藜提取物叶片晒干,加3-5倍重量份数的水溶液回流提取3次,合并滤液,蒸干制成。The extraction method of the quinoa quinoa extract is as follows: dry the leaves of the quinoa quinoa extract, add 3-5 times the weight of the aqueous solution to reflux for extraction three times, combine the filtrates, and evaporate to dryness.

实施例5Example 5

前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于培养基和培养基外加环磷酰胺中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较环磷酰胺IL-15对我们本发明培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were seeded in the medium and the medium plus cyclophosphamide, and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. Compare the effects of cyclophosphamide IL-15 on our culture medium of the present invention on cell proliferation rate, survival rate and cell phenotype.

验结果表明,在培养14天后,CD3+CD56+双阳性细胞百分率:4号培养基为27.2%(图1),实施例4为36.2%,实施例5为37.1%。在4号培养基中添加苞藜提取物和环磷酰胺可以有效提高CD3+CD56+双阳性细胞百分率,CIK细胞活化率提高一倍以上。The experimental results showed that after 14 days of culture, the percentage of CD3 + CD56 + double-positive cells: No. 4 culture medium was 27.2% (Fig. 1), Example 4 was 36.2%, and Example 5 was 37.1%. Adding quinoa quinoa extract and cyclophosphamide to No. 4 medium can effectively increase the percentage of CD3 + CD56 + double-positive cells, and the activation rate of CIK cells is more than doubled.

Claims (5)

1. a kind of immunocyte serum free medium, it is characterised in that medium component includes basal medium, polyamine, pancreas islet Element, cholesterol, ferrum citricum, inositol and antioxidant;The basal medium is RPMI-1640.
2. immunocyte serum free medium according to claim 1, it is characterised in that every liter of culture medium includes:Cholesterol 13.2mg/L;Insulin 20mg/L;Ferrum citricum 2mg/L;NaHCO32g/L;Monoethanolamine 1.22mg/L;Linoleic acid 1mg/L;Flesh Alcohol 19mg/L;Glutaminol 584mg/L;Sodium Pyruvate 110mg/L;2 mercaptoethanol 0.78mg/L;1 thioglycerol 5.41mg/ L;Nonessential amino acid 20ml/L;Vitamin 10ml/L;Polyamine additive 3.31mg/L;Antioxidant 0.52mg/L;Oleic acid 1mg/L。
3. immunocyte serum free medium according to claim 2, it is characterised in that the nonessential amino acid is sweet ammonia In acid, alanine, proline, tyrosine, serine, cysteine, asparagine, glutamine, aspartic acid, glutamic acid It is one or more kinds of.
4. immunocyte serum free medium according to claim 2, it is characterised in that the vitamin is vitamin A, dimension Raw plain B1, vitamin B2, nicotinic acid, adenine phosphate, vitamin B5, vitamin B6, biotin, FA, vitamin B12, inositol, vitamin C, vitamin D, vitamin E, the one or more in vitamin K.
5. immunocyte serum free medium according to claim 1, it is characterised in that the medium component also includes IL-15, IFN-γ, CD3, the one or more in IL-1 α, the IL-2 factors.
CN201710953958.6A 2017-10-13 2017-10-13 A kind of immunocyte serum free medium and preparation method thereof Pending CN107502592A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710953958.6A CN107502592A (en) 2017-10-13 2017-10-13 A kind of immunocyte serum free medium and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710953958.6A CN107502592A (en) 2017-10-13 2017-10-13 A kind of immunocyte serum free medium and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107502592A true CN107502592A (en) 2017-12-22

Family

ID=60700984

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710953958.6A Pending CN107502592A (en) 2017-10-13 2017-10-13 A kind of immunocyte serum free medium and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107502592A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593712A (en) * 2018-12-24 2019-04-09 广东暨德康民生物科技有限责任公司 Immune cell expansion method and immune cell media
CN108004213B (en) * 2018-01-30 2020-09-22 北京汇智驰康生物科技有限公司 Method and kit for rapid amplification of CIK cells
CN112029723A (en) * 2020-09-18 2020-12-04 郑州佐爵生物科技有限公司 Method for culturing umbilical cord blood CIK cells in vitro

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1566331A (en) * 2003-06-27 2005-01-19 北京天润善达生物科技有限责任公司 Serum-free culture medium for lymphocyte
CN104371973A (en) * 2013-08-15 2015-02-25 协和华东干细胞基因工程有限公司 Serum-free medium of immune cells
CN105018423A (en) * 2015-05-27 2015-11-04 贵州北科泛特尔生物科技有限公司 CIK cell culturing method
WO2016091349A1 (en) * 2014-12-11 2016-06-16 Merck Patent Gmbh Cell culture media
CN106635953A (en) * 2016-12-13 2017-05-10 昆明润什生物科技有限公司 Serum-free protein-free cell culture medium
CN106754634A (en) * 2016-12-31 2017-05-31 山东金周生物科技有限公司 A kind of serum free medium and preparation method thereof
CN106834229A (en) * 2017-01-25 2017-06-13 华东理工大学 For the serum free medium of people's immunologic cytotoxicity cell expansion ex vivo

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1566331A (en) * 2003-06-27 2005-01-19 北京天润善达生物科技有限责任公司 Serum-free culture medium for lymphocyte
CN104371973A (en) * 2013-08-15 2015-02-25 协和华东干细胞基因工程有限公司 Serum-free medium of immune cells
WO2016091349A1 (en) * 2014-12-11 2016-06-16 Merck Patent Gmbh Cell culture media
CN105018423A (en) * 2015-05-27 2015-11-04 贵州北科泛特尔生物科技有限公司 CIK cell culturing method
CN106635953A (en) * 2016-12-13 2017-05-10 昆明润什生物科技有限公司 Serum-free protein-free cell culture medium
CN106754634A (en) * 2016-12-31 2017-05-31 山东金周生物科技有限公司 A kind of serum free medium and preparation method thereof
CN106834229A (en) * 2017-01-25 2017-06-13 华东理工大学 For the serum free medium of people's immunologic cytotoxicity cell expansion ex vivo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
徐厚冰: "《菠菜提取物》", 《百度百科》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108004213B (en) * 2018-01-30 2020-09-22 北京汇智驰康生物科技有限公司 Method and kit for rapid amplification of CIK cells
CN109593712A (en) * 2018-12-24 2019-04-09 广东暨德康民生物科技有限责任公司 Immune cell expansion method and immune cell media
CN112029723A (en) * 2020-09-18 2020-12-04 郑州佐爵生物科技有限公司 Method for culturing umbilical cord blood CIK cells in vitro
CN112029723B (en) * 2020-09-18 2021-08-06 陕西中港万海生命科学研究院有限公司 Method for culturing umbilical cord blood CIK cells in vitro

Similar Documents

Publication Publication Date Title
US20080292605A1 (en) Materials for stimulation of hematopoiesis by ex vivo activated cells
CN106190964B (en) A serum-free medium for mesenchymal stem cells
CN107267454A (en) The amplification in vitro method and its kit of a kind of Cord Blood Natural Killer Cells: Impact and application
CN104928241B (en) A kind of activation method and cell preparation method of enhanced NK cells
CN107502592A (en) A kind of immunocyte serum free medium and preparation method thereof
EP3114215A1 (en) Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
CN105524882B (en) Serum substitute for immunologic cytotoxicity cell expansion ex vivo combines
CN112795536A (en) Culture method of human T cells and serum-free medium composition
JP2022504722A (en) Proliferation system for hematopoietic stem cells and hematopoietic progenitor cells
Pochon et al. Wharton’s jelly‐derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation
Najar et al. Cytokinome of adult-derived human liver stem/progenitor cells: immunological and inflammatory features
US20020159984A1 (en) Cultivation of cells for long term engraftment
US20220396766A1 (en) Method for arterial endothelial-enhanced functional t cell generation
WO2022143785A1 (en) Methods for preparing tumor-infiltrating lymphocytes
CN118667759A (en) NK cell serum-free medium
CN104017770B (en) Method for preparing CIK cell by using glycolipid
CN107502589A (en) A kind of tumor infiltrating lymphocyte and mononuclearcell co-culture method
CN114517176B (en) Kit for inducing IPS (in-plane switching) cells into NK (natural killer) cells and application method of kit
CN103966163B (en) Enhancement mode DCIK cell preparation method and cell preparation thereof
CN115044548B (en) Serum-free medium and application thereof
CN113652400B (en) NK cell serum-free medium and application thereof
US7332158B2 (en) Compositions and treatments for myelosuppression by ex vivo activated immune cells
CN104673746B (en) Bone photo closes mescenchymal stem cell Sca1+The preparation and its application of subgroup
CN107090434A (en) A kind of blood anticoagulant and store method for improving CIK cell culture effect
CN118773134B (en) CIK cell culture solution suitable for CIK cell culture and method for culturing CIK cells by using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination